Evogene Secures $3.4 Million from Warrant Inducement Deal to Boost Growth

Evogene Ltd. (NASDAQ: EVGN; TASE: EVGN), a groundbreaking company specializing in computational chemistry and the generative design of small molecules, has successfully negotiated a warrant inducement agreement with an existing institutional investor. This transaction is expected to yield approximately $3.4 million in gross proceeds, enhancing the company’s operational capacity.

The warrant inducement agreement allows for the immediate exercise of existing Series A and Series B ordinary warrants, each permitting the purchase of up to 1.69 million ordinary shares. The exercise will be at a reduced price of $1.00 per share, providing Evogene with vital liquidity. The net cash from this agreement is aimed at bolstering working capital and supporting various corporate functions, reinforcing Evogene's commitment to its strategic growth.

As part of the agreement, the investor will receive new Series A-1 and Series B-1 unregistered warrants, allowing for the purchase of an additional 2.54 million ordinary shares each at an exercise price of $1.25 per share. This initiative represents an innovative mechanism for increasing capital while enabling the institutional investor to benefit from potential future growth.

The timely execution of this transaction is anticipated to occur around February 11, 2026, once standard closing conditions are met. A.G.P./Alliance Global Partners is serving as the sole financial advisor for this transaction, highlighting a strong partnership for financial strategy in this endeavor.

Evogene is known for its proprietary platform, ChemPass AI™, which leverages advanced generative AI technology to design new and highly efficient small molecules intended for the pharmaceutical and agricultural industries. This unique approach enhances the probability of successful outcomes, while also trimming development times and costs, marking a significant advancement in the field of computational chemistry.

The focus on